A pharmacokinetic/pharmacodynamic drug-drug interaction study of tofogliflozin (a new SGLT2 inhibitor) and selected anti-type 2 diabetes mellitus drugs - Kasahara, N; Fukase, H; Ohba, Y (Drug Res (Stuttg), 2016)
et al.